Article

Renal Cell Carcinoma: The Translation of Molecular Biology Into New Treatments, New Patient Outcomes, and Nursing Implications

Nancy P. Moldawer

Robert Figlin

renal cell carcinoma, meta-analysis
ONF 2008, 35(4), 699-708. DOI: 10.1188/08.ONF.699-708

Purpose/Objectives: To provide an overview of the current knowledge and treatment options for renal cell carcinoma (RCC).

Data Sources: Published articles, published abstracts, online databases, and package inserts.

Data Synthesis: Researchers have an increased understanding of the genetic and prognostic risk factors associated with RCC. Most patients with this rare type of cancer have or will develop metastasis. Nephrectomy treats localized disease and cytokine therapy was the previous standard for metastatic disease, but newly approved targeted agents, such as sorafenib, temsirolimus, and sunitinib, as well as investigational agents such as bevacizumab, are improving patient outcomes.

Conclusions: Understanding the biologic basis of RCC has led to therapies that are transforming the goals for treatment outcomes in patients with metastatic disease and increasing time to progression with manageable side effects.

Implications for Nursing: Counseling patients and managing treatment-related side effects of therapy are critical interventions for healthcare professionals caring for patients with RCC. Evolving treatments for metastatic disease are providing better options for patients and changing disease management.

Jump to a section

    References

    Atkins, M. B., Avigan, D. E., Bukowski, R. M., Childs, R. W., Dutcher, J. P., Eisen, T. G., et al. (2004). Innovations and challenges in renal cancer: Consensus statement from the first international conference. Clinical Cancer Research, 10(18, Pt. 2), 6277S-6281S.
    Atkins, M. B., Hidalgo, M., Stadler, W. M., Logan, T. F., Dutcher, J. P., Hudes, G. R., et al. (2004). Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. Journal of Clinical Oncology, 22(5), 909-918.
    Greene, F. L., Page, D. L., Fleming, I. D., Fritz, A. G., Balch, C. M., Haller, D. G., et al. (Eds.). (2002). AJCC cancer staging manual (6th ed.). New York: Springer.
    Hainsworth, J. D., Sosman, J. A., Spigel, D. R., Edwards, D. L., Baughman, C., & Greco, A. (2005). Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. Journal of Clinical Oncology, 23(31), 7889-7896.
    Han, K. R., Pantuck, A. J., & Belldegrun, A. S. (2003). Basic biology and clinical behavior of renal cell carcinoma. Cancer Treatment and Research, 116(1), 69-89.
    Parekh, D. J., Cookson, M. S., Chapman, W., Harrell, F., Jr., Wells, N., Chang, S. S., et al. (2005). Renal cell carcinoma with renal vein and inferior vena caval involvement: Clinicopathological features, surgical techniques and outcomes. Journal of Urology, 173(6), 1897-1902.
    Patard, J. J., Kim, H. L., Lam, J. S., Dorey, F. J., Pantuck, A. J., Zisman, A., et al. (2004). Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: An international multicenter study. Journal of Clinical Oncology, 22(16), 3316-3322.
    Patard, J. J., Leray, E., Rioux-Leclercq, N., Cindolo, L., Ficarra, V., Zisman, A., et al. (2005). Prognostic value of histologic subtypes in renal cell carcinoma: A multicenter experience. Journal of Clinical Oncology, 23(12), 2763-2771.
    Pfizer Inc. (2006). Sutent® (sunitinib malate) capsules prescribing information. Retrieved May 23, 2007, from http://www.sutenthcp.com/prescribing_information.asp
    Rini, B. I., & Small, E. J. (2005). Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. Journal of Clinical Oncology, 23(5), 1028-1043.
    Rioux-Leclercq, N. C., & Epstein, J. I. (2003). Renal cell carcinoma with intratumoral calcium oxalate crystal deposition in patients with acquired cystic disease of the kidney. Archives of Pathology and Laboratory Medicine, 127(2), E89-E92. Retrieved May 15, 2008, from http://arpa.allenpress.com/arpaonline/?request=get-document&doi=10.1043… http://arpa.allenpress.com/arpaonline/?request=get-document&doi=10.1043%2F0003-9985(2003)127%3Ce89:RCCWIC%3E2.0.CO%3B2
    Rosenberg, S. A., Yang, J. C., White, D. E., & Steinberg, S. M. (1998). Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response. Annals of Surgery, 228(3), 307-319.
    Rosenblum, S. L. (1987). Paraneoplastic syndromes associated with renal cell carcinoma. Journal of the South Carolina Medical Association, 83(7), 375-378.
    Storkel, S., Eble, J. N., Adlakha, K., Amin, M., Blute, M. L., Bostwick, D. G., et al. (1997). Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer, 80(5), 987-989.
    Swierzewski, D. J., Swierzewski, M. J., & Libertino, J. A. (1994). Radical nephrectomy in patients with renal cell carcinoma with venous, vena caval, and atrial extension. American Journal of Surgery, 168(2), 205-209.
    Upton, M. P., Parker, R. A., Youmans, A., McDermott, D. F., & Atkins, M. B. (2005). Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. Journal of Immunotherapy, 28(5), 488-495.
    Veronese, M. L., Mosenkis, A., Flaherty, K. T., Gallagher, M., Stevenson, J. P., Townsend, R. R., et al. (2006). Mechanisms of hypertension associated with BAY 43-9006. Journal of Clinical Oncology, 24(9), 1363-1369.
    Vogelzang, N. J. (2006). Treatment options in metastatic renal carcinoma: An embarrassment of riches. Journal of Clinical Oncology, 24(1), 1-3.
    Walther, M. M., Johnson, B., Culley, D., Shah, R., Weber, J., Venzon, D., et al. (1998). Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival. Journal of Urology, 159(3), 718-722.
    Wyeth Pharmaceuticals, Inc. (2007). Torisel® (temsirolimus) 25 mg injection prescribing information. Retrieved May 15, 2008, from http://www.wyeth.com/content/ShowLabeling.asp?id=49
    Motzer, R. J., Rini, B. I., Bukowski, R. M., Curti, B. D., George, D. J., Hudes, G. R., et al. (2006). Sunitinib in patients with metastatic renal cell carcinoma. JAMA, 295(21), 2516-2524.
    National Cancer Institute. (2006). Cancer stat fact sheets: Cancer of the kidney and renal pelvis. Retrieved May 15, 2008, from http://www.seer.cancer.gov/statfacts/html/kidrp.html
    National Comprehensive Cancer Network. (2008). Clinical practice guidelines in oncology: Kidney cancer. Retrieved May 25, 2008, from http://www.nccn.org/professionals/physician_gls/default.asp
    National Institutes of Health. (2006). National Institute of Neurologic Disorders and Stroke. Tuberous sclerosis fact sheet. Retrieved May 23, 2006, from http://www.ninds.nih.gov/disorders/tuberous_sclerosis/detail_tuberous_sclerosis.htm
    Novartis Pharmaceuticals Corporation. (2008). Proleukin® (aldesleukin for injection) prescribing information. Retrieved June 10, 2008, from http://www.proleukin.com/index.jsp
    Onyx Pharmaceuticals and Bayer Pharmaceuticals. (2008). Nexavar® (sorafenib) tablets 200 mg prescribing information. Retrieved June 10, 2008, from http://www.nexavar.com/wt/page/hp_home
    Lam, J. S., Pantuck, A. J., Belldegrun, A. S., & Figlin, R. A. (2005). G250: A carbonic anhydrase IX monoclonal antibody. Current Oncology Reports, 7(2), 109-115.
    Lam, J. S., Shvarts, O., Leppert, J. T., Figlin, R. A., & Belldegrun, A. S. (2005). Renal cell carcinoma 2005: New frontiers in staging, prognostication, and targeted molecular therapy. Journal of Urology, 173(6), 1853-1862.
    Leibovich, B. C., Han, K. R., Bui, M. H., Pantuck, A. J., Dorey, F. J., Figlin, R. A., et al. (2003). Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: A stratification tool for prospective clinical trials. Cancer, 98(12), 2566-2575.
    Linehan, W. M., Vasselli, J., Srinivasan, R., Walther, M. M., Merino, M., Choyke, P., et al. (2004). Genetic basis of cancer of the kidney: Disease-specific approaches to therapy. Clinical Cancer Research, 10(18, Pt. 2), 6282S-6289S.
    McDermott, D. (2005). Cytokine working group: New paradigm in IL-2 therapy based on improved patient selection. Kidney Cancer Journal, 3(1), 5-9.
    McLauglin, S. A., Thiel, D. D., Smith, S. L., Wehle, M. J., & Menke, D. M. (2006). Solitary breast mass as initial presentation of clinically silent metastatic renal cell carcinoma. Breast, 15(3), 427-429.
    Moldawer, N. P., & Wood, L. S. (2006). Integrating the oncology nurse into the new paradigm of targeted therapy in renal cell cancer: Special considerations, initiatives, and guidelines. Kidney Cancer Journal, 4(1), 21-32.
    Motzer, R. J. (2003). Renal cell carcinoma: A priority malignancy for development and study of novel therapies. Journal of Clinical Oncology, 21(7), 1193-1194.
    Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., et al. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine, 356(2), 115-124.
    Motzer, R. J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., & Ferrara, J. (1999). Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. Journal of Clinical Oncology, 17(8), 2530-2540.
    Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., et al. (2006). Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 24(1), 16-24.
    Hock, L. M., Lynch, J., & Balaji, K. C. (2002). Increasing incidence of all stages of kidney cancer in the last two decades in the United States: An analysis of surveillance, epidemiology, and end results program data. Journal of Urology, 167(1), 57-60.
    Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., et al. (2007). Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine, 356(22), 2271-2281.
    Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Taylor, M., et al. (2008). Cancer statistics, 2008. CA: A Cancer Journal for Clinicians, 58(1), 71-96.
    Becker, F., Siemer, S., Hack, M., Humke, U., Ziegler, M., & Stockle, M. (2006). Excellent long-term cancer control with elective nephron-sparing surgery for selected renal cell carcinomas measuring more than 4 cm. European Urology, 49(6), 1058-1064.
    Bleumer, I., Oosterwijk, E., Oosterwijk-Wakka, J. C., Voller, M. C., Melchior, S., Warnaar, S. O., et al. (2006). A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. Journal of Urology, 175(1), 57-62.
    Bui, M. H., Zisman, A., Pantuck, A. J., Han, K. R., Wieder, J., & Belldegrun, A. S. (2001). Prognostic factors and molecular markers for renal cell carcinoma. Expert Review of Anticancer Therapy, 1(4), 565-575.
    Bukowski, R. M., Kabbinavar, F., Figlin, R. A., Flaherty, K., Srinivas, S., Vaishampayan, U., et al. (2006). Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC) [Abstract 4523]. Journal of Clinical Oncology, 24(Suppl.), 222s.
    Cella, D., Yount, S., Du, H., Dhanda, R., Gondek, K., Langefield, K., et al. (2006). Development and validation of the Functional Assessment of Cancer Therapy—Kidney Symptom Index. Journal of Supportive Oncology, 4(4), 191-199.
    Chow, W. H., Devesa, S. S., Warren, J. L., & Fraumeni, J. F., Jr. (1999). Rising incidence of renal cell cancer in the United States. JAMA, 281(17), 1628-1631.
    Chow, W. H., Gridley, G., Fraumeni, J. F., Jr., & Jarvholm, B. (2000). Obesity, hypertension, and the risk of kidney cancer in men. New England Journal of Medicine, 343(18), 1305-1311.
    Cindolo, L., Patard, J. J., Chiodini, P., Schips, L., Ficarra, V., Tostain, J., et al. (2005). Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: A multicenter European study. Cancer, 104(7), 1362-1371.
    Cohen, H. T., & McGovern, F. J. (2005). Renal-cell carcinoma. New England Journal of Medicine, 353(23), 2477-2490.
    Curti, B. D. (2004). Renal cell carcinoma. JAMA, 292(1), 97-100.
    Desai, M. M., & Gill, I. S. (2002). Current status of cryoablation and radio-frequency ablation in the management of renal tumors. Current Opinion in Urology, 12(5), 387-393.
    Dimashkieh, H., Choe, J., & Mutema, G. (2003). Renal medullary carcinoma: A report of 2 cases and review of the literature. Archives of Pathology and Laboratory Medicine, 127(3), e135-e138. Retrieved May 15, 2008, from http://arpa.allenpress.com/arpaonline/?request=get-document&doi=10.1043… http://arpa.allenpress.com/arpaonline/?request=get-document&doi=10.1043%2F0003-9985(2003)127%3Ce135:RMCARO%3E2.0.CO%3B2
    Donat, S. M., Salzhauer, E. W., Mitra, N., Yanke, B. V., Snyder, M. E., & Russo, P. (2006). Impact of body mass index on survival of patients with surgically treated renal cell carcinoma. Journal of Urology, 175(1), 46-52.
    Donskov, F., & von der Maase, H. (2006). Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. Journal of Clinical Oncology, 24(13), 1997-2005.
    Elmore, J. M., Kadesky, K. T., Koeneman, K. S., & Sagalowsky, A. I. (2003). Reassessment of the 1997 TNM classification system for renal cell carcinoma. Cancer, 98(11), 2329-2334.
    Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., et al. (2007). Sorafenib in advanced clear-cell renal-cell carcinoma. New England Journal of Medicine, 356(2), 125-134.
    Fahn, H. J., Lee, Y. H., Chen, M. T., Huang, J. K., Chen, K. K., & Chang, L. S. (1991). The incidence and prognostic significance of humoral hypercalcemia in renal cell carcinoma. Journal of Urology, 145(2), 248-250.
    Ficarra, V., Righetti, R., Pilloni, S., D'amico, A., Maffei, N., Novella, G., et al. (2002). Prognostic factors in patients with renal cell carcinoma: Retrospective analysis of 675 cases. European Urology, 41(2), 190-198.
    Fisher, R. I., Rosenberg, S. A., & Fyfe, G. (2000). Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer Journal from Scientific American, 6(Suppl. 1), S55-S57.
    Flanigan, R. C. (2004). Debulking nephrectomy in metastatic renal cancer. Clinical Cancer Research, 10(18, Pt. 2), 6335S-6341S.
    Fouladbakhsh, J. M., Stommel, M., Given, B. A., & Given, C. W. (2005). Predictors of use of complementary and alternative therapies among patients with cancer. Oncology Nursing Forum, 32(6), 1115-1122.
    Fuhrman, S. A., Lasky, L. C., & Limas, C. (1982). Prognostic significance of morphologic parameters in renal cell carcinoma. American Journal of Surgical Pathology, 6(7), 655-663.
    George, D. J., & Kaelin, W. G., Jr. (2003). The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. New England Journal of Medicine, 349(5), 419-421.
    Ghavamian, R., Cheville, J. C., Lohse, C. M., Weaver, A. L., Zincke, H., & Blute, M. L. (2002). Renal cell carcinoma in the solitary kidney: An analysis of complications and outcome after nephron sparing surgery. Journal of Urology, 168(2), 454-459.
    Ghavamian, R., & Zincke, H. (2001). Open surgical partial nephrectomy. Seminars in Urologic Oncology, 19(2), 103-113.
    Giarelli, E. (2006). Self-surveillance for genetic predisposition to cancer: Behaviors and emotions. Oncology Nursing Forum, 33(2), 221-231.
    American Cancer Society. (2006). Cancer facts and figures 2006. Retrieved May 11, 2006, from http://www.cancer.org/downloads/STT/CAFF2006PWSecured.pdf